Search
-
Election Action: Why businesses need to prepare today for 2024’s uncertainty
No one knows who will win America’s election – but we can forecast what might happen under a Trump or Biden presidency. Here’s why brands need to act on that today.
-
What the Future: Risk
In this foresight webinar, we explore the social and commercial ramifications of uncertainty across industries. Revisit our recording to hear valuable takeaways on how to ensure your risks are calculated ones.
-
Why panel-member first is good for research and business
The KnowledgePanel employs a highly effective approach to online probability research that emphasizes the experience and life cycle of panel members, something we call the Panel-Member First Approach.
-
Are we prepared for population decline?
New research from Ipsos’ 2024 Generations Report underscores why it’s more important to tailor communications, product development and service delivery to the values and expectations of different age cohorts.
-
Ipsos Update – May 2024
Earth, plastics, politics … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
What Regulators Need to Know About Third-Party App Installers
If regulators want to create a competitive app installer market, consumers must be able to have a fast, easy download experience, while still feeling safe.
-
Brand Biden vs Brand Trump
The power of empathy in a story of brand decline - revisit our insights to see how Americans perceive the presidential candidates as political brands.
-
The Power of the ESG x Brand Collaboration
Read more about how ESG activities can work in service of the brand to strengthen brand equity.
-
Shifting Shoppers’ ESG Attitudes to Action
Discover how ESG plays out for shoppers, manufacturers and retailers, what the roles and responsibilities are for each party, and how understanding and the use of relevant information can incentivize shoppers to change behaviors.
-
The Patient Perspective: Evaluating Time and Treatment While Living with Metastatic Breast Cancer
The results of this research demonstrate the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan.